Alfredo Paredes

427 total citations
20 papers, 344 citations indexed

About

Alfredo Paredes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alfredo Paredes has authored 20 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alfredo Paredes's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (8 papers). Alfredo Paredes is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (8 papers). Alfredo Paredes collaborates with scholars based in Spain, United States and France. Alfredo Paredes's co-authors include Á. Artal, Dolores Isla, Manuel Dómine, I. Barneto, M. López-Brea, Carlos Camps, José Javier Sánchez, Rafael Rosell, Miquel Tarón and Carme Sarries and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

Alfredo Paredes

18 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfredo Paredes Spain	7	192	191	170	74	35	20	344
R. Di Marsico Italy	5	235 1.2×	145 0.8×	154 0.9×	130 1.8×	29 0.8×	10	356
Mónica Botia Spain	5	272 1.4×	318 1.7×	247 1.5×	150 2.0×	56 1.6×	6	518
Davide Mari Italy	7	115 0.6×	210 1.1×	83 0.5×	40 0.5×	90 2.6×	8	358
Annelieke E.C.A.B. Willemsen Netherlands	10	145 0.8×	89 0.5×	102 0.6×	23 0.3×	17 0.5×	25	298
Alexey Moisseev Russia	7	123 0.6×	139 0.7×	57 0.3×	45 0.6×	17 0.5×	11	289
Marek Jasiówka Poland	7	276 1.4×	123 0.6×	180 1.1×	171 2.3×	15 0.4×	16	432
J. Luna Spain	10	101 0.5×	80 0.4×	121 0.7×	50 0.7×	36 1.0×	23	322
Adam Szpechciński Poland	11	127 0.7×	226 1.2×	200 1.2×	308 4.2×	24 0.7×	32	469
Sabine Glaser Switzerland	5	137 0.7×	104 0.5×	211 1.2×	49 0.7×	52 1.5×	8	296
J. Schüller Austria	11	251 1.3×	58 0.3×	69 0.4×	36 0.5×	61 1.7×	30	351

Countries citing papers authored by Alfredo Paredes

Since Specialization

Citations

This map shows the geographic impact of Alfredo Paredes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfredo Paredes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfredo Paredes more than expected).

Fields of papers citing papers by Alfredo Paredes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfredo Paredes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfredo Paredes. The network helps show where Alfredo Paredes may publish in the future.

Co-authorship network of co-authors of Alfredo Paredes

This figure shows the co-authorship network connecting the top 25 collaborators of Alfredo Paredes. A scholar is included among the top collaborators of Alfredo Paredes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfredo Paredes. Alfredo Paredes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boni, Valentina, Barbara Pistilli, Irene Braña, et al.. (2022). Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 7(5). 100571–100571. 8 indexed citations

Seoane, José A., et al.. (2022). Fortalezas y debilidades de la regulación española de la eutanasia. 255–260.

Bernabé, Reyes, Pilar Garrido, Rosario García‐Campelo, et al.. (2022). Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 13(1). 812–827. 3 indexed citations

Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations

Paredes, Alfredo, Teresa Morán, Bartomeu Massutí, et al.. (2020). ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Revista Española de Patología. 53(3). 140–148. 2 indexed citations

Mar, Javier, et al.. (2020). Changes in lung cancer survival by TNM stage in the Basque country from 2003 to 2014 according to period of diagnosis. Cancer Epidemiology. 65. 101668–101668. 3 indexed citations

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

Isla, Dolores, Margarita Majem, M. Guirado, et al.. (2018). NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 8537–8537. 1 indexed citations

Arriola, Edurne, Alfredo Paredes, Ramón García Gómez, et al.. (2016). 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. Journal of Thoracic Oncology. 11(4). S122–S122. 1 indexed citations

10.

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2014). Observational retrospective study to describe the management of advanced epidermal growth factor receptor (EGFR) mutated (M+) non-small cell lung cancer (NSCLC) patients (pts) in Spain (NCT01795352).. Journal of Clinical Oncology. 32(15_suppl). e19133–e19133. 2 indexed citations

11.

Provencio, Mariano, Manuel Cobo, Sergio Vázquez‐Estévez, et al.. (2010). Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment.. Journal of Clinical Oncology. 28(15_suppl). e18109–e18109. 1 indexed citations

12.

Otterburn, David M., Alfredo Paredes, & Roderick T. Hester. (2009). Overnight Observation in Stand-Alone Surgicenters. Annals of Plastic Surgery. 62(5). 502–504. 1 indexed citations

13.

Paredes, Alfredo, et al.. (2009). 9149 Phase II study of bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (p) with metastatic non squamous non-small-cell lung cancer (NSCLC). European Journal of Cancer Supplements. 7(2). 550–550. 1 indexed citations

14.

Paredes, Alfredo, et al.. (2009). Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). e19023–e19023. 2 indexed citations

15.

Martinez, Eliana C., et al.. (2008). Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: A prospective randomized phase II study. Journal of Clinical Oncology. 26(15_suppl). 7563–7563. 14 indexed citations

16.

Paredes, Alfredo, et al.. (2008). Bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (pts) with advanced or metastatic, non squamous, non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 19109–19109. 2 indexed citations

17.

Pallarés, Cinta, Jaume Capdevila, Alfredo Paredes, et al.. (2007). Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial. Lung Cancer. 58(2). 238–245. 10 indexed citations

18.

Paredes, Alfredo, et al.. (2006). Expresión de proteínas relacionadas con resistencia a múltiples fármacos (MDR-proteínas) en tumores sólidos. Cirugía Española. 79(4). 202–214. 2 indexed citations

19.

Isla, Dolores, Carme Sarries, Rafael Rosell, et al.. (2004). Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology. 15(8). 1194–1203. 255 indexed citations

20.

Felip, Enriqueta, Rafael Rosell, Vicente Alberola, et al.. (2000). Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. Clinical Lung Cancer. 1(4). 287–293. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact